Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Holding FULC?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.28Last Year’s EPS
-$0.4Same Quarter Last Year
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: 19.51%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Neutral
The earnings call presented some key positive developments, such as a strong financial position, progress in the pociredir program, and strategic leadership changes. However, these were balanced by significant setbacks, including the suspension of the losmapimod program and a notable workforce reduction. The financial outlook remains stable, despite zero collaboration revenue and a net loss. Overall, the call reflects a balanced sentiment with both positive and negative elements.Company Guidance
During Fulcrum Therapeutics' Q3 2024 earnings call, the company provided guidance on its strategic focus and financial outlook. Following the disappointing results from the Phase III REACH trial of losmapimod, which did not meet primary or key secondary endpoints, Fulcrum decided to suspend its development, resulting in a workforce reduction of about 40%. The company is now channeling its resources towards advancing pociredir for sickle cell disease, with a Phase Ib trial called the PIONEER trial underway, and plans to report data in 2025. Financially, Fulcrum reported a cash position of $257.2 million as of September 30, 2024, and guided for a cash burn of approximately $55 million to $65 million in 2025. The company expects its cash reserves to support operations into at least 2027, allowing it to fund its ongoing and future development programs.Strong Financial Position
Fulcrum reported cash, cash equivalents, and marketable securities of $257.2 million as of September 30, 2024, up from $236.2 million at the end of 2023.
Progress in Pociredir Development
The company is advancing pociredir, an oral HBF inducer for sickle cell disease, with ongoing Phase Ib PIONEER trial and plans to initiate Phase I trials in healthy volunteers.
New Leadership and Board Appointments
Rachel King joined the Board of Directors, and Dr. Thomas Winkler was appointed Vice President of Hematology for clinical development.
Reduced Operating Expenses
Research and development expenses decreased by $3.6 million, and general and administrative expenses decreased by $1.6 million compared to Q3 2023.
---
FULC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FULC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $3.64 | $3.56 | -2.20% |
| Jul 31, 2024 | $8.41 | $9.28 | +10.34% |
| May 13, 2024 | $7.47 | $7.35 | -1.61% |
| Feb 27, 2024 | $9.73 | $10.18 | +4.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fulcrum Therapeutics (FULC) report earnings?
Fulcrum Therapeutics (FULC) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Fulcrum Therapeutics (FULC) earnings time?
Fulcrum Therapeutics (FULC) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FULC EPS forecast?
FULC EPS forecast for the fiscal quarter 2024 (Q4) is -$0.28.
---